Oligo-antigenic Diet in the Treatment of Chronic Anal Fissures.
|ClinicalTrials.gov Identifier: NCT01637857|
Recruitment Status : Completed
First Posted : July 11, 2012
Last Update Posted : January 11, 2013
|Condition or disease||Intervention/treatment|
|Anal Fissures Treatment and Oligoantigenic Diet||Dietary Supplement: sham oligoantigenic diet associated to lifestyle instruction Dietary Supplement: oligoantigenic diet|
Context: Patients with chronic constipation due to food hypersensitivity (FH) had an elevated anal sphincter resting pressure. No studies have investigated a possible role of FH in anal fissures (AF).
Objective: We aim to evaluate 1) the effectiveness of a diet in curing AF; 2) the clinical effects of a double-blind placebo controlled (DBPC) challenge with cow's milk protein or wheat.
Design: The study will have two different parts: the first to verify the effectiveness of the oligo-antigenic diet in chronic AF treatment; the second to search for a possible cause-effect relationship between the diet and the onset of the AF.
Setting: We will enrol consecutive adult patients with chronic AF who will refer to a Surgical Department of the University of Palermo for a 3-years period. Inclusion criteria are: evidence of CAF evaluated by an experienced rectal surgeon; patient age >16 years. Exclusion criteria are: a diagnosis of inflammatory bowel disease, ongoing steroid treatment performed for any reason, an exclusion diet followed for any reason, and pregnancy. At the time of the first evaluation, routine laboratory tests, immunology tests, rectal biopsies and anal-rectal manometry will be performed.
Patients: patients, finally included in the study, will be randomized to one of the treatment groups.
Interventions: Enrolled patients will be randomized to receive a "true elimination diet" or a "sham elimination diet"; both groups will also receive topical nifedipine and lidocaine.
Main Outcome Measures: The patients will be evaluated every two weeks for CAF persistence or healing; anal pain will be scored on a visual analogue scale ranging from 0 (absence of pain) to 10 (intolerable pain). Anal-rectal manometry will be repeated at the end of the study period, in all patients who will be treated.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||161 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Oligo-antigenic Diet in the Treatment of Chronic Anal Fissures. Evidence for a Relationship Between Food Hypersensitivity and Anal Fissures|
|Study Start Date :||January 2006|
|Primary Completion Date :||December 2009|
|Study Completion Date :||December 2010|
Sham Comparator: lifestyle counseling
Group of patients treated with sham oligoantigenic diet
Dietary Supplement: sham oligoantigenic diet associated to lifestyle instruction
sham oligoantigenic diet associated to lifestyle instruction
Experimental: oligoantigenic diet
Treatment with oligoantigenic diat
Dietary Supplement: oligoantigenic diet
oligoantigenic diet associated to life style counseling
- Chronic anal fissures persistence or healing [ Time Frame: 2 years ]The patients will be evaluated every two weeks for eight weeks for CAF persistence or healing; anal pain will be scored on a visual analogue scale ranging from 0 (absence of pain) to 10 (intolerable pain). Anal-rectal manometry will be repeated at the end of the study period, in all patients who will be treated.
- Anal fissures recurring after Double-Blind Placebo-Controlled food challenge [ Time Frame: 2 years ]In this part of the study will be included patients with healed chronic anal fissures on true elimination diet (GROUP B) plus patients of GROUP A, who received "sham elimination diet", uncured, were offered the treatment option of "true elimination diet" before undergoing surgery, accepted, and finally cured. Therefore, we will evaluate anal fissures recurring after Double-Blind Placebo-Controlled Food Challenges with cow's milk and wheat, and Open Challenges with other foods (i.e. egg, tomato and chocolate).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01637857
|Surgery Department, University of Palermo, Italy|
|Palermo, Italy, 90127|
|Study Director:||Antonio Carroccio, Prof.||Internal Medicine, Hospital of Sciacca, ASP Agrigento, University of Palermo, Italy|
|Principal Investigator:||Pasquale Mansueto, Dr.||University of Palermo|
|Principal Investigator:||Sebastiano Bonventre, Dr.||University of Palermo|